Get the Stockscreener App
10.99
0.18%
-0.02
Contineum Therapeutics Inc stock is traded at $10.99, with a volume of 3,891.
It is down -0.18% in the last 24 hours and down -3.17% over the past month.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
See More
Previous Close:
$11.01
Open:
$11
24h Volume:
3,891
Relative Volume:
0.02
Market Cap:
$237.44M
Revenue:
-
Net Income/Loss:
$-35.46M
P/E Ratio:
-26.06
EPS:
-0.4218
Net Cash Flow:
$-34.00M
1W Performance:
-1.96%
1M Performance:
-3.17%
6M Performance:
+168.05%
1Y Performance:
-33.99%
1-Day Range:
$10.75
$11.00
1-Week Range:
$10.36
$11.23
52-Week Range:
$3.35
$20.24
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
10.98 | 321.30M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.69 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.02 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.18 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
825.84 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.89 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Leerink Partners | Outperform |
| Jun-20-25 | Initiated | William Blair | Outperform |
| Oct-22-24 | Initiated | Robert W. Baird | Outperform |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Apr-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-30-24 | Initiated | Stifel | Buy |
View All
Contineum Therapeutics Inc Stock (CTNM) Latest News
Real time social sentiment graph for Contineum Therapeutics Inc.July 2025 Momentum & Daily Chart Pattern Signals - newser.com
Live market analysis of Contineum Therapeutics Inc.July 2025 Opening Moves & Community Consensus Stock Picks - newser.com
Why retail investors pile into Contineum Therapeutics Inc. stockJuly 2025 Patterns & Fast Moving Trade Plans - newser.com
How Contineum Therapeutics Inc. stock compares to growth peersEntry Point & Scalable Portfolio Growth Ideas - newser.com
How Contineum Therapeutics Inc. stock reacts to inflationary pressuresCEO Change & Fast Momentum Stock Entry Tips - newser.com
Volatility clustering patterns for Contineum Therapeutics Inc.July 2025 Breakouts & AI Optimized Trade Strategies - newser.com
Can Contineum Therapeutics Inc. stock outperform in 2025 bull market2025 Valuation Update & Fast Exit/Entry Strategy Plans - newser.com
Risk adjusted return profile for Contineum Therapeutics Inc. analyzedJuly 2025 Summary & Stock Timing and Entry Methods - newser.com
What momentum shifts mean for Contineum Therapeutics Inc.2025 Market Sentiment & Free Safe Capital Growth Stock Tips - newser.com
Will Contineum Therapeutics Inc. stock split attract more investors2025 Major Catalysts & Consistent Profit Alerts - newser.com
Contineum Therapeutics Inc. stock momentum explainedJuly 2025 Short Interest & Smart Money Movement Alerts - newser.com
Using Ichimoku Cloud for Contineum Therapeutics Inc. technicalsJuly 2025 Highlights & High Accuracy Investment Entry Signals - newser.com
Contineum Therapeutics (NASDAQ:CTNM) Issues Quarterly Earnings Results - MarketBeat
Using data models to predict Contineum Therapeutics Inc. stock movementPortfolio Gains Report & Daily Technical Stock Forecast Reports - newser.com
Buy Rating for Contineum Therapeutics: Promising Advancements in Clinical Pipeline and Strategic Opportunities - TipRanks
Is Contineum Therapeutics Inc. building a consolidation baseWeekly Trend Recap & Short-Term Swing Trade Alerts - newser.com
What makes RF Acquisition Corp II stock price move sharply - newser.com
Building trade automation scripts for Contineum Therapeutics Inc.2025 Momentum Check & Reliable Entry Point Trade Alerts - newser.com
Is it time to cut losses on Contineum Therapeutics Inc.2025 Sector Review & Real-Time Market Sentiment Reports - newser.com
Contineum Therapeutics Reports Increased R&D Investment Amid Losses - TipRanks
Is Contineum Therapeutics Inc. stock attractive for growth ETFsJuly 2025 Earnings & Long Hold Capital Preservation Tips - newser.com
Visual trend scoring systems applied to Contineum Therapeutics Inc.July 2025 Patterns & Daily Profit Maximizing Tips - newser.com
[10-Q] Contineum Therapeutics, Inc. Quarterly Earnings Report | CTNM SEC FilingForm 10-Q - Stock Titan
CTNM 8-K: Q3 2025 results press release furnished (Exhibit 99.1) - Stock Titan
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - Business Wire
Contineum Therapeutics (CTNM) Expected to Announce Earnings on Wednesday - MarketBeat
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):